US FDA ‘State Of Quality’ Report Targets Unreviewed, Uninspected Risks
Executive Summary
The poorest-quality pharmaceuticals consumed in the US are the ones FDA has never reviewed, or are from sites the agency has never inspected, regardless of country of origin; the agency’s inaugural ‘State of Quality’ report contains some surprising findings.
You may also be interested in...
US FDA’s Machine Learning Analysis Suggests Where To Look For Manufacturing Site Quality Problems
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.
Drug Quality Focus On Asia, OTCs Supported By US FDA's Second GMP Data Report
OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.
Drug Quality Focus On Asia, OTCs Supported By New US FDA Data
OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.